Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine

Core Insights - Clearmind Medicine Inc. is participating in the Psychedelic Medicine – Israel 2024 conference, which will take place from July 28th to 30th in Tel Aviv, Israel, focusing on psychedelic medicine advancements [1][3] Company Overview - Clearmind is a clinical-stage biotech company dedicated to the discovery and development of novel psychedelic-derived therapeutics aimed at addressing significant under-treated health issues, including alcohol use disorder [9] - The company currently holds an intellectual property portfolio consisting of eighteen patent families and 28 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [4] Research Presentations - Notable presentations at the conference include research on 5-methoxy-2-aminoindane (MEAI), a mild psychedelic agent, which has shown potential in reducing diet-induced obesity and regulating binge behaviors [6][11] - Dr. Zullof-Shani, CEO of Clearmind, will present on MEAI's potential as a binge behavior regulator, highlighting its innovative application in addiction treatment [8][11] - Research findings indicate that MEAI significantly reduces fat mass, preserves lean mass, improves glucose metabolism, reduces hepatic steatosis, and increases energy expenditure in a diet-induced obesity mouse model [13]